Mustafin, R.N.,
Bermisheva, M.A.,
Karunas, A.S.,
Akhmetshin, A.A.,
Monakhova, A.S.,
Khusnutdinova, E.K. (2025) _001035957.
1:p.Glu19Ter), NM_001042492.
3:c.2806A>T (NP_001035957.
1:p.Lys936Ter), NM_001042492.
3:c.3284T
Introduction:
3-ethoxythietane-
1,1-dioxide (
3ETD) is a novel molecule that has demonstrated
.9 μm (examiner
1), -2.9 ± 18.6 μm (examiner 2), and 10.5 ± 21.8 μm (examiner
3), respectively
Bikbov, Mukharram M.,
Kazakbaeva, Gyulli M.,
Iakupova, Ellina M.,
Fakhretdinova, Albina A.,
Gilmanshin, Timur R.,
Panda-Jonas, Songhomitra,
Jonas, Jost B. (2025) (OR:
3.34; 95% CI:2.37,4.71; P < 0.001), and with older age (OR:
1.12; 95% CI:
1.04,1.19; P = 0
Gao, Xin,
Huang, Yanming,
Wei, Tonghui,
Xue, Jingmin,
Iurii, Filippov,
Yang, Laishou,
Wang, Liying,
Li, Hao,
Mo, Genshen,
Huang, Yuze,
Xie, Haonan,
Wang, Hang,
Lou, Shenghan,
Han, Peng (2025) the ubiquitin-mediated degradation of RIPK
3, thereby reducing the sensitivity of CC cells to 5-fluorouracil (5
Usmanova, Irina N.,
Yunusova, Rita D.,
Lakman, Irina А.,
Gerasimova, Larisa P.,
Ishmukhametova, Amina N.,
Akopyan, Anait P.,
Amineva, Gulfina F.,
Makarova, Natalia А.,
Startseva, Elena Yu. (2025) .9% and 28.57% of CD patients and in 14.
3% and 8.6% of UC patients (KACD =
1.0, KAUC = 0.64). In CD patients
Blinov, Andrey,
Nagdalian, Andrey,
Rzhepakovsky, Igor,
Rekhman, Zafar,
Askerova, Alina,
Agzamov, Vadim,
Kayumov, Umedzhon,
Tairov, Dilshod,
Ibrahimov, Sobirzhon,
Sayahov, Ilgiz (2025) their biocompatibility and toxicity. For the synthesis of CC-NPs, Cu(CH
3COO)2 and CuCl2 were used as Cu precursors, while